KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Receivables: 2010-2025

Historic Receivables for Emergent BioSolutions (EBS) over the last 15 years, with Sep 2025 value amounting to $168.8 million.

  • Emergent BioSolutions' Receivables rose 20.14% to $168.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $680.2 million, marking a year-over-year decrease of 27.39%. This contributed to the annual value of $174.1 million for FY2024, which is 28.18% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Receivables stood at $168.8 million, which was up 64.36% from $102.7 million recorded in Q2 2025.
  • Emergent BioSolutions' Receivables' 5-year high stood at $341.9 million during Q2 2023, with a 5-year trough of $102.7 million in Q2 2025.
  • Its 3-year average for Receivables is $222.0 million, with a median of $234.6 million in 2025.
  • Per our database at Business Quant, Emergent BioSolutions' Receivables surged by 48.59% in 2023 and then slumped by 63.16% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Receivables (Quarterly) stood at $330.5 million in 2021, then tumbled by 34.52% to $216.4 million in 2022, then rose by 12.01% to $242.4 million in 2023, then dropped by 28.18% to $174.1 million in 2024, then rose by 20.14% to $168.8 million in 2025.
  • Its Receivables was $168.8 million in Q3 2025, compared to $102.7 million in Q2 2025 and $234.6 million in Q1 2025.